SRP-3D is under clinical development by South Rampart Pharma and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SRP-3D’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SRP-3D overview

SRP-3D is under development as an oral formulation for the treatment of fever, chronic pain, diabetic neuropathic pain, chemotherapy neuropathic pain and other neuropathic pain syndromes, as an ophthalmic formulation for ocular pain, as an intravenous formulation for acute pain and intravenous formulation for treatment of fever. It is an analog of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide.

South Rampart Pharma overview

South Rampart Pharma is a developer of drugs for treating acute, chronic, and neuropathic pain. The company is headquartered in New Orleans, Louisiana, the US.

For a complete picture of SRP-3D’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.